Abstract 1488P
Background
Platinum-based chemotherapy (CT) with PDL-1 blockade is the standard of care in ES-SCLC. Relevant randomized controlled trials were restricted to patients(pts) with ECOG PS 0-1 at initiation of therapy. These trials also prohibited use of consolidation radiotherapy (RT) or salvage RT to treat of oligo-progression. We aimed to evaluate outcomes in pts with poor ECOG PS and those receiving non-palliative RT, as well as the prevalence and outcomes of durvalumab (DRV) beyond progression.
Methods
A retrospective data collection including pts from 11 centers in four countries. Primary endpoints were overall survival (OS) and duration of treatment (DOT) in the overall population and in the subgroup of pts with ECOG ≥2. Secondary endpoints included safety, OS and DOT in pts treated with non-palliative RT as well as the use of ICI beyond progression.
Results
A total of 100 pts received durvalumab with CT for ES-SCLC. 68% were male, median age was 65 years (range 39-83) and 23% had an ECOG ≥2. Overall, 29% of patients received RT during durvalumab treatment, 22% as salvage/consolidation. Fifteen pts (15%) were treated with DRV beyond progression for a median of 4 cycles (range 1-14). Median OS in the entire cohort was 11.5mo, 13.3mo in pts with ECOG 0-1 and 10.3mo in pts with ECOG ≥2 (p=0.028). Median DOT in the entire cohort was 4.5mo and 4.2 in pts with ECOG ≥2 (p=0.006). Pts receiving non-palliative RT showed a trend toward improved OS and DOT (Table). Eight pts (8%) discontinued DRV due to immune-related adverse events. Table: 1488P
mDOT and mOS in pts receiving non-palliative RT
| All patients | Pts with consolidation/salvage RT | P-VALUE | |
| mDOT with durvalumab (months) | 4.5 | 5.9 | 0.056 |
| mOS (months) | 11.5 | 14.7 | 0.190 |
Conclusions
Treatment with CT and DRV is safe and effective in pts with ES-SCLC with ECOG PS ≥2 as well as in pts receiving concomitant radiotherapy. Treatment discontinuation rate due to toxicity was comparable to that reported in the CASPIAN study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21